Skip to main content
. 2021 Sep 25;13(2):643–667. doi: 10.1016/j.jcmgh.2021.09.014

Figure 1.

Figure 1

KDM6A mutations and expression profiles and their association with survival in human PDACs. (A) Sequencing data of human PDACs (N = 168) were queried from TCGA PanCancer Atlas database and PDACs with KDM6A mutations are highlighted by various colored bars. (B) Number of lymph nodes positive for metastatic PDAC in patients with high- or low-KDM6A-expressing PDACs (TCGA, N = 22). (C and D) Kaplan–Meier survival curves of (C) overall and (D) disease-specific survival in patients with KDM6A-mutated (Mut) or wild-type (WT) PDAC based on TCGA PanCancer Atlas data sets. (E) IHC staining scores of KDM6A in normal/pancreatitis (n = 36), PanIN (n = 32), mucinous cystic neoplasm (MCN, n = 13), intraductal papillary mucinous neoplasm (IPMN, n = 39), primary PDACs (PDAC, n = 74) and metastatic PDACs (MET, n = 19) from a human pancreas TMA. (F) Representative images of H&E and KDM6A IHC staining of the pancreas TMA with pancreata in different stages of PDAC progression. ∗P < .05, ∗∗∗∗P < .0001, unpaired t test.